<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379752</url>
  </required_header>
  <id_info>
    <org_study_id>20200501</org_study_id>
    <nct_id>NCT04379752</nct_id>
  </id_info>
  <brief_title>Cold Plasma to Treat Hair Loss</brief_title>
  <official_title>Using Indirect Cold Atmospheric Pressure Plasma (Plasma Activate Liquid) for the Treatment of Hair Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Peter C. Friedman</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Skin Center Dermatology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Self applied cold plasma activated medium used for androgenetic alopecia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 8, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of detectable hair growth</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Presence of hair growth is observed clinically. Evaluation may include photo comparison, hair count, trichoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects related to the treatment</measure>
    <time_frame>throughout study completeion, 6 months</time_frame>
    <description>Patients are monitored for adverse effects, including but not limited to irritation, itch, inflammation, scaling, redness, rash, peeling, blistering</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Cold-atmospeheric pressure plasma activated solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment arm subjects receive the trial intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment</intervention_name>
    <description>Cold plasma is generated and applied to carrier liquid. Subjects are provided with the liquid to apply to the treated area</description>
    <arm_group_label>Cold-atmospeheric pressure plasma activated solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of mild-to moderate androgenetic alopecia

          -  ability of applying treatment regularly

          -  ability to keep in-person follow-up appointments

        Exclusion Criteria:

          -  any inflammatory scalp condition

          -  starting or discontinuing any hair loss treatments within 6 months of start date

          -  allergy to any components of the carrier solution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Skin Center Dermatology Group</name>
      <address>
        <city>New City</city>
        <state>New York</state>
        <zip>10956</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter C Friedman, MD, PhD</last_name>
      <phone>845-352-0500</phone>
      <email>pbc9@columbia.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Skin Center Dermatology Group</investigator_affiliation>
    <investigator_full_name>Dr. Peter C. Friedman</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

